Given the central role these key pathways play in the pathogenesis of LUAD, developing drugs to block the abnormal interactions between tumor cells and B cells or to regulate key molecules for the humoral immune response pathways, as well as developing CDK inhibitors or restoring the Rb-E2F pathway function through gene therapy for the cell-cycle-related pathways, represents promising therapeutic strategies for LUAD treatment. Here, RB1 is linked to neoplasm.